Last update July 5, 2022
Very Low Risk
SSRI antidepressant with actions and uses similar to those of fluoxetine. Oral administration once daily.
It is excreted in breast milk in small amounts although occasionally with a relative dose greater than 10%. (Pogliani 2019, Schoretsanitis 2019, Weisskopf 2017, Rampono 2000, Schmidt 2000, Jensen 1997, Spigset 1997)
Serum levels of infants from breastfeeding mothers who were treated have been shown to be undetectable or very low. (Berle 2004, Heikkinen 2002, Nordeng 2001, Rampono 2000)
Although there are some isolated cases of transient sleep disturbances, irritability or colic (Kronenfeld 2018, Schmidt 2000, Lee 2004), no short-term or long-term problems have been observed in the majority of infants whose mothers took it. (Werremeyer 2009, Berle 2004, Hendrick 2003, Rampono 2000, Jensen 1997)
Transient troubles in the early neonatal period like drug withdrawal syndrome among newborn or premature infants with high serum levels as a result of treatment with citalopram to the mother during pregnancy have been observed. (Erol 2017, Kieviet 2015, Franssen 2006, Nordeng 2001)
Galactorrhea associated or not to hyperprolactinemia, may appear. (Türkoğlu 2016, Trenque 2011, Koch 2011, Wessels 2006, González 2001).
Several medical societies, experts and expert consensus, consider the use of this medication safe or probably safe during breastfeeding. (Hale, Lactmed, Uguz 2021, Rubin 2004, Wisner 2002)
Safer known alternatives are preferable, especially during the neonatal period and in cases of prematurity. (Weisskopf 2017, Sriraman 2015, Larsen 2015, Sachs 2013, Rowe 2013, Berle 2011, Patil 2011, Davanzo 2010, Lanza 2009, ABM 2008, Weissman 2004, Gjerdingen 2003, Nordeng 2001)
Women suffering from depression during pregnancy need more breastfeeding support due to their increased risk of breastfeeding problems and early weaning. (Grzeskowiak 2018, Leggett 2017, Gorman 2012)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM